Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gabapentin--a new antiepileptic agent]

K O Nakken1, E Rytter, S I Johannessen

  • 1Statens senter for epilepsi, Sandvika.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|April 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased rate of acute caesarean sections in women with epilepsy: results from the Oppland Perinatal Database in Norway.

European journal of neurology·2018
Same author

Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs.

Acta neurologica Scandinavica·2016
Same author

Capturing metal-support interactions in situ during the reduction of a Re promoted Co/γ-Al2O3 catalyst.

Chemical communications (Cambridge, England)·2016
Same author

Favorable change of lipid profile after carbamazepine withdrawal.

Acta neurologica Scandinavica·2015
Same author

Retention rate of zonisamide in intractable epilepsy.

Acta neurologica Scandinavica·2015
Same author

Modified Atkins diet may reduce serum concentrations of antiepileptic drugs.

Acta neurologica Scandinavica·2014

Gabapentin, an antiepileptic drug, showed moderate seizure reduction in 25 patients with refractory partial seizures. While well-tolerated, optimal dosing for gabapentin may require further investigation.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Gabapentin is an antiepileptic drug with an unclear mechanism of action, potentially differing from existing treatments.
  • Its favorable pharmacokinetic profile suggests ease of administration.

Purpose of the Study:

  • To present preliminary clinical observations of gabapentin use.
  • To evaluate the efficacy and tolerability of gabapentin in patients with refractory epilepsy.

Main Methods:

  • A cohort of 58 adult patients with refractory partial seizures received gabapentin as an add-on therapy.
  • The average follow-up period was 6.9 months.

Main Results:

  • 25 patients experienced a moderate seizure reduction (10-50%), with one patient showing over 50% reduction.

Related Experiment Videos

  • The most favorable clinical effects were observed in patients with secondary generalized tonic-clonic seizures.
  • Gabapentin was generally well-tolerated with no significant drug interactions.

    • Conclusions:

    • Gabapentin demonstrated moderate efficacy in a subset of patients with refractory epilepsy.
    • The drug was well-tolerated, suggesting potential as an adjunctive therapy.
    • Further studies are needed to determine optimal gabapentin dosing, as current doses may be sub-therapeutic.